Collectively, these results highlight the efficacy of immunotherapy combining ACT plus tumor antigen-specific vaccination and confirmed the strong potential of a donor-unrestricted ACT approach for acute leukemia with CD1c-retargeted T cells. This evidence concerns the gene CD1C and acute leukemia.